VP3.15
Catalog No. A18538
VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS).
| Catalog Num | A18538 |
|---|---|
| M. Wt | 366.48 |
| Formula | C20H22N4OS |
| Purity | >98% |
| Storage | at -20°C 3 years Powder |
| CAS No. | 1281681-54-6 |
| Synonyms | VP315, VP-3.15 |
| SMILES | N1(CC/N=C2N=C(C3=CC=CC=C3)N(C4=CC=CC=C4)S/2)CCOCC1 |
VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS).
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 27.29 mL | 136.43 mL | 272.87 mL |
| 0.5 mM | 5.46 mL | 27.29 mL | 54.57 mL |
| 1 mM | 2.73 mL | 13.64 mL | 27.29 mL |
| 5 mM | 0.55 mL | 2.73 mL | 5.46 mL |
*The above data is based on the productmolecular weight 366.48. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
Contact information
United StatesAdooq Bioscience
Toll Free: (866) 930-6790
Fax: +1-323-606-8156
Email: sales@adooq.com
ADOOQ 产品质量保证
We promise all products to perform as described.